StockTipsArenaBeta

BUY Piramal Pharma Limited — Dharmesh Shah, ICICI Securities

BUYPiramal Pharma Limited
Piramal Pharma share price target & all analyst calls

byDharmesh Shah, ICICI SecuritiesHorizon: NA (inferred Swing (≤2wk))20 Jul 2026via LiveMint Markets

Entry₹176.5Stated
Target₹190
Total upside +7.65% (call closed)
Stop loss₹169-4.25% risk
Exit₹19027 Jul 2026, 10:00 am
Target hit+7.65%0.00%upside left
Follow Dharmesh Shah for new callsGet alertsWatch PPLPHARMA for new buy/sell callsGet alertsSee 236 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 27 Jul 2026
3 supporting2 neutral3 opposing
Supports the BUY call (3)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·21 Jul · 5d ago

Piramal Pharma, Authum Investment, Vaibhav Global: शेअर बाजारात दिसले 'टेक्निकल ब्रेकआउट'चे संकेत!

NewsGoogle News·20 Jul · 1w ago

(opens in new tab)

1 advisor has an active short-term BUY call on this stock

Advisor consensus · adjacent horizon·27 May · 2mo ago

Neutral / worth noting (2)

Piramal Pharma temporarily suspends Ahmedabad plant operations due to heavy rainfall

NewsCnbc-Tv18·25 Jul · 2d ago

(opens in new tab)

Piramal Pharma, Authum Investment, Vaibhav Global Show Technical Breakouts

NewsGoogle News·20 Jul · 1w ago

(opens in new tab)
Weighs against the BUY call (3)

HDFC Mutual Fund reduces stake in Piramal Pharma by 2.005%

NewsGoogle News·18 Jul · 1w ago

(opens in new tab)

HDFC Mutual Fund Sells 2% Stake in Piramal Pharma

NewsGoogle News·17 Jul · 1w ago

(opens in new tab)

HDFC Mutual Fund ने Piramal Pharma मधील हिस्सा विकला, मोठी घट!

NewsGoogle News·17 Jul · 1w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Piramal Pharma

All analyst calls on Piramal Pharma

More from Dharmesh Shah, ICICI Securities

Every call and its outcome